Medical Ikkou Group Co., Ltd. (3353) AI Stock Analysis

• Market Cap: ¥10.71B
• Dividend Yield: 0.97%
• Average Volume (3M): 15.75K
• Price to Earnings (P/E): 10.2
• Beta (1Y): 0.44
• Revenue Growth: 19.52%
• EPS Growth: -9.23%
• Country: JP
• Employees: 1,431
• Sector: Industrials
• Sector Strength: 86
• Industry: Conglomerates
• EPS (TTM): 116.49
• Shares Outstanding: 3,770,000
• 10 Day Avg. Volume: 10,770
• 30 Day Avg. Volume: 15,753
• PEG Ratio: -1.63
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 82 Outperform
• Price Target: ¥4,114.00 ▲(36.23%Upside)

The stock score is strong, primarily driven by strong financial performance with robust revenue growth and operational efficiency. Technical analysis supports a bullish trend, while reasonable valuation adds to its attractiveness. However, cash flow challenges and a modest dividend yield are potential concerns.

Medical Ikkou Group Co., Ltd. Business Overview & Revenue Model

Company Description

Medical Ikkou Group Co., Ltd. (3353) is a Japan-based company primarily engaged in the pharmaceutical and healthcare sectors. The company operates a chain of pharmacies, offering prescription medications, over-the-counter drugs, and health-related products. Additionally, it provides home delivery services for pharmaceuticals and engages in the sale of medical equipment. The group aims to enhance community health through its comprehensive healthcare solutions and expert pharmaceutical services.

How the Company Makes Money

Medical Ikkou Group Co., Ltd. generates revenue primarily through its network of pharmacy stores, which sell prescription medications and over-the-counter drugs to individuals. Another significant revenue stream comes from the sale of health-related products, including nutritional supplements and wellness goods. The company also earns income by offering home delivery services for pharmaceuticals, providing convenience to customers who need medications delivered to their homes. Additionally, Medical Ikkou Group sells medical equipment to healthcare institutions and individuals, further diversifying its revenue streams. Partnerships with pharmaceutical manufacturers and healthcare providers play a crucial role in expanding its product offerings and maintaining competitive pricing, thereby contributing to its overall earnings.

Medical Ikkou Group Co., Ltd. Financial Statement Overview

Summary

Medical Ikkou Group Co., Ltd. demonstrates strong revenue growth and operational efficiency, but faces challenges in net profitability and cash flow management. The balance sheet reflects stability with a healthy equity ratio and manageable debt levels. While the income statement shows a positive growth trajectory, cash flow constraints could impact future financial flexibility.

Income Statement

Medical Ikkou Group Co., Ltd. has shown strong revenue growth with a 21.3% increase from 2024 to 2025. The gross profit margin has improved to 11.6% in 2025 from 11.4% in 2024, indicating better cost management. The EBIT margin also improved to 3.5% in 2025 from 3.9% in 2024, showcasing operational efficiency. However, the net profit margin remained stable at around 2.3%, suggesting room for improvement in net profitability.

Balance Sheet

The company maintains a healthy equity ratio of 41.2% in 2025, reflecting strong solvency. The debt-to-equity ratio decreased to 0.71 in 2025 from 0.72 in 2024, showing effective debt management. ROE was stable at 8.0% in 2025, indicating consistent return on shareholders' equity. However, the total debt level remains significant, which could pose a risk if not managed properly.

Cash Flow

Operating cash flow decreased significantly to ¥1.2 billion in 2025 from ¥4.3 billion in 2024, negatively impacting free cash flow, which dropped by 94.9%. The free cash flow to net income ratio declined, signaling potential cash flow issues relative to earnings. However, the company generated positive free cash flow, indicating some level of operational efficiency.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	48.39B	39.90B	33.90B	33.60B	31.60B
Gross Profit	5.61B	4.55B	3.18B	3.61B	3.20B
EBITDA	2.73B	2.50B	2.21B	2.41B	2.33B
Net Income	1.13B	1.04B	759.60M	852.33M	834.99M
Balance Sheet
Total Assets	34.23B	31.66B	27.51B	29.09B	28.55B
Cash, Cash Equivalents and Short-Term Investments	6.77B	7.70B	6.44B	7.99B	7.00B
Total Debt	10.02B	9.58B	9.12B	11.31B	11.85B
Total Liabilities	19.52B	17.82B	14.90B	17.17B	18.07B
Stockholders Equity	14.10B	13.24B	12.05B	11.38B	10.48B
Cash Flow
Free Cash Flow	201.34M	3.95B	960.14M	798.00M	1.33B
Operating Cash Flow	1.20B	4.28B	1.31B	1.14B	1.82B
Investing Cash Flow	-1.13B	-3.22B	-477.52M	-215.52M	-1.18B
Financing Cash Flow	-1.03B	277.76M	-2.37B	64.74M	590.88M

Medical Ikkou Group Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3020.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3353, the sentiment is Neutral. The current price of 3020 is below the 20-day moving average (MA) of 3043.25, above the 50-day MA of 2689.06, and above the 200-day MA of 2290.31, indicating a neutral trend. The MACD of 124.72 indicates Positive momentum. The RSI at 52.24 is Neutral, neither overbought nor oversold. The STOCH value of 6.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3353.

Medical Ikkou Group Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3353	82 Outperform	¥10.71B	10.21		0.97%	19.52%	-9.23%
6554	78 Outperform	¥10.75B	12.72		2.52%	19.85%	78.11%
7670	77 Outperform	¥9.86B	5.56		3.62%	-2.30%	16.63%
7066	74 Outperform	¥6.28B	11.65		2.56%	7.60%	37.77%
7490	74 Outperform	¥7.66B	12.45		2.18%	0.78%	106.93%
7795	66 Neutral	¥8.04B	11.24		4.05%	5.00%	25.91%
Sector *	58 Neutral	HK$14.20B	4.67	-2.78%	5.88%	3.78%	-54.63%